Literature DB >> 30512964

Decreased levels of miR-28-5p and miR-361-3p and increased levels of insulin-like growth factor 1 mRNA in mononuclear cells from patients with hereditary hemorrhagic telangiectasia 1.

Anthony Cannavicci1,2, Qiuwang Zhang2, Si-Cheng Dai2, Marie E Faughnan3, Michael J B Kutryk1,2.   

Abstract

Hereditary hemorrhagic telangiectasia (HHT) is a rare vascular disorder inherited in an autosomal dominant manner. Patients with HHT can develop vascular dysplasias called telangiectasias and arteriovenous malformations (AVMs). Our objective was to profile and characterize micro-RNAs (miRNAs), short noncoding RNAs that regulate gene expression posttranscriptionally, in HHT patient-derived peripheral blood mononuclear cells (PBMCs). PBMCs, comprised mostly of lymphocytes and monocytes, have been reported to be dysfunctional in HHT. A total of 40 clinically confirmed HHT patients and 22 controls were enrolled in this study. PBMCs were isolated from 16 mL of peripheral blood and purified for total RNA. MiRNA expression profiling was conducted with a human miRNA array analysis. Select dysregulated miRNAs and miRNA targets were validated with reverse transcription-quantitative polymerase chain reaction. Of the 377 miRNAs screened, 41 dysregulated miRNAs were identified. Both miR-28-5p and miR-361-3p, known to target insulin-like growth factor 1 (IGF1), a potent angiogenic growth factor, were found to be significantly downregulated in HHT patients. Consequently, IGF1 mRNA levels were found to be significantly elevated. Our research successfully identified miRNA dysregulation and elevated IGF1 mRNA levels in PBMCs from HHT patients. This novel discovery represents a potential pathogenic mechanism that could be targeted to alleviate clinical manifestations of HHT.

Entities:  

Keywords:  cellules mononucléées de sang périphérique; dysrégulation des microARN; hereditary hemorrhagic telangiectasia; microRNA dysregulation; peripheral blood mononuclear cells; télangiectasie hémorragique familiale

Mesh:

Substances:

Year:  2018        PMID: 30512964      PMCID: PMC6886744          DOI: 10.1139/cjpp-2018-0508

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  54 in total

Review 1.  Regulation of angiogenesis by Th1- and Th2-type cytokines.

Authors:  A Naldini; A Pucci; C Bernini; F Carraro
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

2.  Microarray analysis of microRNA expression patterns in the semen of infertile men with semen abnormalities.

Authors:  Te Liu; Weiwei Cheng; Yongtao Gao; Hui Wang; Zhixue Liu
Journal:  Mol Med Rep       Date:  2012-06-25       Impact factor: 2.952

Review 3.  TGF-beta signaling in vascular biology and dysfunction.

Authors:  Marie-José Goumans; Zhen Liu; Peter ten Dijke
Journal:  Cell Res       Date:  2009-01       Impact factor: 25.617

4.  Elevated circulating microRNA-210 levels in patients with hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations: a potential new biomarker.

Authors:  Qiuwang Zhang; Ivana Kandic; Marie E Faughnan; Michael J Kutryk
Journal:  Biomarkers       Date:  2012-10-10       Impact factor: 2.658

5.  Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome).

Authors:  C L Shovlin; A E Guttmacher; E Buscarini; M E Faughnan; R H Hyland; C J Westermann; A D Kjeldsen; H Plauchu
Journal:  Am J Med Genet       Date:  2000-03-06

6.  Enhancing engineered vascular networks in vitro and in vivo: The effects of IGF1 on vascular development and durability.

Authors:  Claudia C Friedrich; Yunfeng Lin; Alexander Krannich; Yinan Wu; Joseph P Vacanti; Craig M Neville
Journal:  Cell Prolif       Date:  2017-11-07       Impact factor: 6.831

7.  Unraveling the global microRNAome responses to ionizing radiation in human embryonic stem cells.

Authors:  Mykyta V Sokolov; Irina V Panyutin; Ronald D Neumann
Journal:  PLoS One       Date:  2012-02-08       Impact factor: 3.240

8.  Mouse models of hereditary hemorrhagic telangiectasia: recent advances and future challenges.

Authors:  Simon Tual-Chalot; S Paul Oh; Helen M Arthur
Journal:  Front Genet       Date:  2015-02-18       Impact factor: 4.599

9.  DIANA-miRPath v3.0: deciphering microRNA function with experimental support.

Authors:  Ioannis S Vlachos; Konstantinos Zagganas; Maria D Paraskevopoulou; Georgios Georgakilas; Dimitra Karagkouni; Thanasis Vergoulis; Theodore Dalamagas; Artemis G Hatzigeorgiou
Journal:  Nucleic Acids Res       Date:  2015-05-14       Impact factor: 16.971

10.  DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA-gene interactions.

Authors:  Dimitra Karagkouni; Maria D Paraskevopoulou; Serafeim Chatzopoulos; Ioannis S Vlachos; Spyros Tastsoglou; Ilias Kanellos; Dimitris Papadimitriou; Ioannis Kavakiotis; Sofia Maniou; Giorgos Skoufos; Thanasis Vergoulis; Theodore Dalamagas; Artemis G Hatzigeorgiou
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

View more
  4 in total

Review 1.  Molecular and genetic mechanisms in brain arteriovenous malformations: new insights and future perspectives.

Authors:  Sandra Vetiska; Thomas Wälchli; Ivan Radovanovic; Moncef Berhouma
Journal:  Neurosurg Rev       Date:  2022-10-11       Impact factor: 2.800

2.  Reduction of endoglin receptor impairs mononuclear cell-migration.

Authors:  Zhenying Han; Sonali Shaligram; Marie E Faughnan; Dewi Clark; Zhengda Sun; Hua Su
Journal:  Explor Med       Date:  2020-06-29

3.  MicroRNA-132-3p, Downregulated in Myeloid Angiogenic Cells from Hereditary Hemorrhagic Telangiectasia Patients, Is Enriched in the TGFβ and PI3K/AKT Signalling Pathways.

Authors:  Anthony Cannavicci; Qiuwang Zhang; Marie E Faughnan; Michael J B Kutryk
Journal:  Genes (Basel)       Date:  2022-04-09       Impact factor: 4.141

Review 4.  Non-Coding RNAs and Hereditary Hemorrhagic Telangiectasia.

Authors:  Anthony Cannavicci; Qiuwang Zhang; Michael J B Kutryk
Journal:  J Clin Med       Date:  2020-10-17       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.